Thousands of lives saved by the NHS thanks to rapid rollout of blood thinners

Thousands of lives saved by the NHS thanks to rapid rollout of blood thinners

Thousands of lives have been saved and almost 17,000 strokes prevented, thanks to the rapid rollout of blood-thinning drugs on the NHS, the head of the health service is due to announce today.

The news comes as the NHS celebrates the one-year anniversary of its Long Term Plan, which set out a bold vision for the future of the health service. The plan includes a commitment to invest in early detection and treatment of cardiovascular conditions, and the rollout of blood-thinning drugs is a key part of this.

Blood-thinning drugs, also known as anticoagulants, work by preventing blood clots from forming. This is important for people with atrial fibrillation (AF), a condition that can cause an irregular and often abnormally fast heart rate. AF is the most common cause of stroke, and people with AF are five times more likely to have a stroke than those without the condition.

Anna Pritchard

The NHS has invested heavily in the rollout of blood-thinning drugs in recent years. In 2021, the NHS reached a commercial agreement with four pharmaceutical companies to ensure that four potentially life-saving DOACs could reach hundreds of thousands more patients at pace.

As a result of this investment, the number of people taking blood-thinning drugs has increased significantly. In the last 18 months, around 460,000 more people have started taking anticoagulant drugs, with more than 24 million prescriptions given to patients.

This has had a dramatic impact on the number of strokes prevented. According to the NHS, the rollout of blood-thinning drugs has prevented an estimated 17,000 strokes and 4,000 deaths in the last two years.

Speaking at Kings Fund Annual Conference later today, NHS chief executive, Amanda Pritchard will say: "It's outstanding news that these drugs have potentially helped save thousands of lives already and prevented many more people from suffering the serious and often debilitating effects of strokes.

"Thanks to hardworking NHS teams across the country, the rapid rollout of these drugs is a monumental step forward in providing the best possible care for patients with cardiovascular conditions.

"It is also part of a major NHS drive to prevent ill health in the first place - we want to reduce the number of people living with major illness and save thousands more lives."

The Stroke Association's associate director for policy and research, Dr Maeva May, said: "It's fantastic news that oral anticoagulants have helped to prevent so many strokes over the last two years. AF accounts for one in five strokes and strokes in people with AF are more severe and are more likely to result in death or serious disability.

"The good news is that if AF is identified it can be managed. The majority of AF related strokes are preventable with the right medication. Managing AF correctly improves people's quality of life and is cost effective for the system. Both AF and other stroke prevention measures must continue to be prioritised regionally and nationally."

Photo Credit: iStock

NHE March/April 2024

NHE March/April 2024

A window into the past, present and future of healthcare leadership.

- Steve Gulati, University of Birmingham 

More articles...

View all
Online Conference

Presenting

2024 Online Conferences

In partnership with our community of health sector leaders responsible for delivering the UK's health strategy across the NHS and the wider health sector, we’ve devised a collaborative calendar of conferences and events for industry leaders to listen, learn and collaborate through engaging and immersive conversation. 

All our conferences are CPD accredited, which means you can gain points to advance your career by attending our online conferences. Also, the contents are available on demand so you can re-watch at your convenience.

National Health Executive Podcast

Ep 42. Leadership in the NHS

In episode 42 of the National Health Executive podcast we were joined by Steve Gulati who is an associate professor at the University of Birmingham as well as director of healthcare leadership at the university’s Health Services Management Centre.